JP2022166014A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022166014A5 JP2022166014A5 JP2022118437A JP2022118437A JP2022166014A5 JP 2022166014 A5 JP2022166014 A5 JP 2022166014A5 JP 2022118437 A JP2022118437 A JP 2022118437A JP 2022118437 A JP2022118437 A JP 2022118437A JP 2022166014 A5 JP2022166014 A5 JP 2022166014A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- biomarker
- caspase
- sample
- therapeutic compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662276700P | 2016-01-08 | 2016-01-08 | |
| US62/276,700 | 2016-01-08 | ||
| US201662404638P | 2016-10-05 | 2016-10-05 | |
| US62/404,638 | 2016-10-05 | ||
| JP2018535307A JP6880037B2 (ja) | 2016-01-08 | 2017-01-06 | がんの治療方法と、治療法に対する臨床的感度の予測因子としてのバイオマーカーの使用 |
| JP2021077686A JP7113942B2 (ja) | 2016-01-08 | 2021-04-30 | がんの治療方法と、治療法に対する臨床的感度の予測因子としてのバイオマーカーの使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021077686A Division JP7113942B2 (ja) | 2016-01-08 | 2021-04-30 | がんの治療方法と、治療法に対する臨床的感度の予測因子としてのバイオマーカーの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022166014A JP2022166014A (ja) | 2022-11-01 |
| JP2022166014A5 true JP2022166014A5 (enExample) | 2023-02-02 |
Family
ID=59274055
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018535307A Active JP6880037B2 (ja) | 2016-01-08 | 2017-01-06 | がんの治療方法と、治療法に対する臨床的感度の予測因子としてのバイオマーカーの使用 |
| JP2021077686A Active JP7113942B2 (ja) | 2016-01-08 | 2021-04-30 | がんの治療方法と、治療法に対する臨床的感度の予測因子としてのバイオマーカーの使用 |
| JP2022118437A Pending JP2022166014A (ja) | 2016-01-08 | 2022-07-26 | がんの治療方法と、治療法に対する臨床的感度の予測因子としてのバイオマーカーの使用 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018535307A Active JP6880037B2 (ja) | 2016-01-08 | 2017-01-06 | がんの治療方法と、治療法に対する臨床的感度の予測因子としてのバイオマーカーの使用 |
| JP2021077686A Active JP7113942B2 (ja) | 2016-01-08 | 2021-04-30 | がんの治療方法と、治療法に対する臨床的感度の予測因子としてのバイオマーカーの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10648983B2 (enExample) |
| EP (1) | EP3399980B1 (enExample) |
| JP (3) | JP6880037B2 (enExample) |
| KR (1) | KR20180095094A (enExample) |
| AU (1) | AU2017205170B2 (enExample) |
| CA (1) | CA3010801A1 (enExample) |
| ES (1) | ES3042541T3 (enExample) |
| IL (2) | IL296659A (enExample) |
| MX (1) | MX390772B (enExample) |
| WO (1) | WO2017120446A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015085172A2 (en) | 2013-12-06 | 2015-06-11 | Celgene Corporation | Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers |
| WO2016196580A1 (en) | 2015-06-02 | 2016-12-08 | Celgene Corporation | Methods for determining drug efficacy for treatment of cancer using ratios of cereblon associated proteins |
| AU2016326499A1 (en) | 2015-09-25 | 2018-04-12 | Celgene Corporation | Methods for treating diffuse large B-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs |
| EP3399980B1 (en) | 2016-01-08 | 2025-07-16 | Celgene Corporation | Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies |
| WO2019121869A1 (en) * | 2017-12-20 | 2019-06-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method of selection of an ire1-inhibitor therapy for patient suffering from cancer |
| US10584133B2 (en) | 2018-03-30 | 2020-03-10 | Biotheryx, Inc. | Thienopyrimidinone compounds |
| IL278854B2 (en) * | 2018-05-23 | 2026-01-01 | Celgene Corp | Multiple myeloma treatment and biomarker use for 4-(4-(4-(((2-(6,2-dioxopyridin-3-yl)-1-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-1-yl-3-fluorobenzonitrile |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| CN114761400B (zh) * | 2019-09-12 | 2024-08-13 | 南京明德新药研发有限公司 | 一种可降解蛋白的并环类化合物及其应用 |
| BR112022007996A2 (pt) * | 2019-10-28 | 2022-07-05 | Celgene Corp | Métodos para o tratamento e uso de biomarcadores para predizer a sensibilidade clínica à 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida |
| US20220378773A1 (en) * | 2019-10-28 | 2022-12-01 | Celgene Corporation | Methods for treating leukemia and use of a leukemic stem cell signature to predict clinical sensitivity to therapies |
| US11031119B2 (en) * | 2019-11-13 | 2021-06-08 | Cube Click, Inc. | Dental images processed with deep learning for national security |
| IL293481A (en) * | 2019-12-06 | 2022-08-01 | Celgene Corp | Processes for the preparation of 2-(4-chlorophenyl)-n-((2-(2,6-dioxypyridin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
| KR102311390B1 (ko) * | 2020-03-03 | 2021-10-13 | 이화여자대학교 산학협력단 | 교모세포종 예후예측용 조성물 |
| US20230149379A1 (en) * | 2020-03-16 | 2023-05-18 | Celgene Corporation | Combination therapy for acute myeloid leukemia |
| WO2021211742A1 (en) * | 2020-04-14 | 2021-10-21 | The General Hospital Corporation | Use of gcn2 inhibitors in treating mitochondrial myopathies and diseases associated with mitochondrial dysfunction |
| WO2021260110A1 (en) | 2020-06-25 | 2021-12-30 | Tolremo Therapeutics Ag | Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of fibrotic disease |
| AU2021298154A1 (en) | 2020-06-25 | 2023-02-23 | Tolremo Therapeutics Ag | Combination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for the treatment of cancer |
| WO2022066835A1 (en) | 2020-09-23 | 2022-03-31 | St. Jude Children's Research Hospital, Inc. | Substituted n-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)arylsulfonamide analogs as modulators of cereblon protein |
| CN117242060B (zh) | 2021-01-13 | 2026-07-17 | 蒙特罗莎治疗股份有限公司 | 异吲哚啉酮化合物 |
| WO2022152822A1 (en) * | 2021-01-13 | 2022-07-21 | Monte Rosa Therapeutics Ag | Treatment of myc-driven cancers with gspt1 degraders |
| GB202104635D0 (en) * | 2021-03-31 | 2021-05-12 | Imperial College Innovations Ltd | Methods and compositions for identifying and treating GCN2-dependent cancers |
| CA3212085C (en) * | 2021-04-07 | 2025-02-11 | Tolremo Therapeutics Ag | HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT OR RELIEF OF CANCER |
| WO2022219412A1 (en) * | 2021-04-14 | 2022-10-20 | Monte Rosa Therapeutics Ag | Isoindolinone amide compounds useful to treat diseases associated with gspt1 |
| WO2023085785A1 (ko) | 2021-11-09 | 2023-05-19 | 한국화학연구원 | 글루타이미드 모핵을 갖는 이소인돌리논 유도체 및 이의 용도 |
| KR102823538B1 (ko) | 2021-11-09 | 2025-06-23 | 한국화학연구원 | 글루타이미드 모핵을 갖는 이소인돌리논 유도체 및 이의 용도 |
| CN114660289A (zh) * | 2022-03-03 | 2022-06-24 | 中山大学附属第三医院 | 肝癌标志物及其应用 |
| EP4508044A1 (en) * | 2022-04-14 | 2025-02-19 | Bristol-Myers Squibb Company | Novel gspt1 compounds and methods of use of the novel compounds |
| US20240115557A1 (en) * | 2022-07-29 | 2024-04-11 | The Brigham And Women's Hospital, Inc. | Inhibitors of rna-guided nucleases and uses thereof |
| EP4581014A1 (en) * | 2022-09-02 | 2025-07-09 | Deciphera Pharmaceuticals, LLC | Ulk inhibitors and methods of use thereof |
| CN120322242A (zh) * | 2022-09-16 | 2025-07-15 | 联邦高等教育系统天普大学 | Bag3用于治疗心脏淀粉样变性的方法和用途 |
| KR20240066906A (ko) | 2022-11-08 | 2024-05-16 | 주식회사 온코드바이오 | 퀴놀린 아마이드 구조를 갖는 이소인돌리논 유도체 및 이의 용도 |
| KR20240066904A (ko) | 2022-11-08 | 2024-05-16 | 주식회사 온코드바이오 | 아릴시클로알킬아마이드 구조를 갖는 이소인돌리논 유도체 및 이의 용도 |
| KR102570883B1 (ko) * | 2023-04-13 | 2023-08-29 | (주) 사이러스테라퓨틱스 | 신규한 gspt1 분해제 및 이의 용도 |
| WO2025164957A1 (ko) * | 2024-01-31 | 2025-08-07 | 남부대학교산학협력단 | 인간화된 세레브론 넉인 마우스 모델 및 이를 이용한 다발성 골수종 항암화학요법의 효능 평가 방법 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1574740A (en) * | 1924-04-07 | 1926-02-23 | Raynor John Roscoe | Cutting device |
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US4044126A (en) | 1972-04-20 | 1977-08-23 | Allen & Hanburys Limited | Steroidal aerosol compositions and process for the preparation thereof |
| GB1429184A (en) | 1972-04-20 | 1976-03-24 | Allen & Hanburys Ltd | Physically anti-inflammatory steroids for use in aerosols |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| KR890002631B1 (ko) | 1984-10-04 | 1989-07-21 | 몬산토 캄파니 | 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물 |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| WO1993018186A1 (en) | 1992-03-04 | 1993-09-16 | The Regents Of The University Of California | Comparative genomic hybridization (cgh) |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| DE69632684T2 (de) | 1995-06-27 | 2005-06-09 | Takeda Pharmaceutical Co. Ltd. | Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung |
| TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
| JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
| US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
| ES2221019T3 (es) | 1996-10-31 | 2004-12-16 | Takeda Chemical Industries, Ltd. | Preparacion de liberacion mantenida. |
| EP0946169B1 (en) | 1996-12-20 | 2003-02-26 | Takeda Chemical Industries, Ltd. | Method of producing a sustained-release preparation |
| US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| GB0103527D0 (en) | 2001-02-13 | 2001-03-28 | Eastman Kodak Co | Photographic developing composition and use thereof in the development of a photographic element |
| US7122799B2 (en) | 2003-12-18 | 2006-10-17 | Palo Alto Research Center Incorporated | LED or laser enabled real-time PCR system and spectrophotometer |
| MX2007014537A (es) * | 2005-05-18 | 2008-02-12 | Wyeth Corp | Genes de la enfermedad de la leucemia y sus usos. |
| CA2957226C (en) | 2008-10-29 | 2018-08-14 | Celgene Corporation | Isoindoline compounds for use in the treatment of cancer |
| TWI509247B (zh) | 2010-03-12 | 2015-11-21 | 西建公司 | 利用雷那度胺（ｌｅｎａｌｉｄｏｍｉｄｅ）治療非霍奇金氏淋巴瘤之方法及作為預測子之基因及蛋白質生物標記 |
| EP2699091B1 (en) | 2011-03-28 | 2017-06-21 | DeuteRx, LLC | 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds |
| WO2012149299A2 (en) | 2011-04-29 | 2012-11-01 | Celgene Corporaiton | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
| ES2872967T3 (es) | 2012-06-29 | 2021-11-03 | Celgene Corp | Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS) |
| WO2014179661A1 (en) * | 2013-05-03 | 2014-11-06 | Celgene Corporation | Methods for treating cancer using combination therapy |
| WO2015085172A2 (en) | 2013-12-06 | 2015-06-11 | Celgene Corporation | Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers |
| BR112016012792A2 (pt) | 2013-12-06 | 2017-08-08 | Celgene Corp | Métodos para o tratamento de cânceres hematológicos e o uso de biomarcadores como um preditor de sensibilidade clínica a terapias imunomoduladoras |
| US9499514B2 (en) * | 2014-07-11 | 2016-11-22 | Celgene Corporation | Antiproliferative compounds and methods of use thereof |
| JP2017533727A (ja) | 2014-10-13 | 2017-11-16 | セルジーン コーポレイション | 固形腫瘍の治療方法及び免疫調節療法への臨床的感度の予測因子としてのバイオマーカーの使用 |
| WO2016196580A1 (en) | 2015-06-02 | 2016-12-08 | Celgene Corporation | Methods for determining drug efficacy for treatment of cancer using ratios of cereblon associated proteins |
| US20170038387A1 (en) | 2015-08-04 | 2017-02-09 | Celgene Corporation | Methods for treating chronic lymphocytic leukemia and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies |
| US20180231561A1 (en) | 2015-08-12 | 2018-08-16 | Celgene Corporation | Methods for treating solid tumors and the use of biomarkers as a predictor of clinical sensitivity to immunomodulatory therapies |
| AU2016326499A1 (en) | 2015-09-25 | 2018-04-12 | Celgene Corporation | Methods for treating diffuse large B-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs |
| CA3010794A1 (en) * | 2016-01-08 | 2017-07-13 | Celgene Corporation | Solid forms of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses |
| EP3399980B1 (en) | 2016-01-08 | 2025-07-16 | Celgene Corporation | Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies |
| US10052315B2 (en) * | 2016-01-08 | 2018-08-21 | Celgene Corporation | Formulations of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
| SG11201809501PA (en) * | 2016-06-06 | 2018-12-28 | Celgene Corp | Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
-
2017
- 2017-01-06 EP EP17736415.5A patent/EP3399980B1/en active Active
- 2017-01-06 CA CA3010801A patent/CA3010801A1/en active Pending
- 2017-01-06 ES ES17736415T patent/ES3042541T3/es active Active
- 2017-01-06 JP JP2018535307A patent/JP6880037B2/ja active Active
- 2017-01-06 US US15/400,766 patent/US10648983B2/en active Active
- 2017-01-06 KR KR1020187022882A patent/KR20180095094A/ko not_active Ceased
- 2017-01-06 WO PCT/US2017/012496 patent/WO2017120446A1/en not_active Ceased
- 2017-01-06 IL IL296659A patent/IL296659A/en unknown
- 2017-01-06 MX MX2018008421A patent/MX390772B/es unknown
- 2017-01-06 AU AU2017205170A patent/AU2017205170B2/en active Active
-
2018
- 2018-07-03 IL IL260400A patent/IL260400B2/en unknown
-
2020
- 2020-04-03 US US16/840,299 patent/US11460471B2/en active Active
-
2021
- 2021-04-30 JP JP2021077686A patent/JP7113942B2/ja active Active
-
2022
- 2022-07-26 JP JP2022118437A patent/JP2022166014A/ja active Pending
- 2022-08-05 US US17/882,278 patent/US12474342B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021121799A5 (enExample) | ||
| JP2017538104A5 (enExample) | ||
| US11207324B2 (en) | Treatment of HER2 positive cancers | |
| JP2022082565A (ja) | がんを処置するための方法 | |
| US20230310455A1 (en) | Combination therapies for treatment of her2 cancer | |
| Janku et al. | Molecular profiling of tumor tissue and plasma cell-free DNA from patients with non-Langerhans cell histiocytosis | |
| JP2022527133A (ja) | マクロファージの活性を調節する方法 | |
| Falini et al. | How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors | |
| JP2018535951A5 (enExample) | ||
| EP3089747A1 (en) | Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer | |
| JP2010507096A (ja) | 有機化合物 | |
| JP2019502708A5 (enExample) | ||
| JP2019507114A5 (enExample) | ||
| Blackwell et al. | Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor | |
| BR112020020246A2 (pt) | Inibidores de cinase axl e uso dos mesmos | |
| AU2016274585A1 (en) | Methods of treating cancer using anti-OX40 antibodies | |
| JP2022513255A (ja) | ＨＤＭ２－ｐ５３相互作用阻害剤とＢＣＬ２阻害剤との組み合わせ及び癌を処置するためのその使用 | |
| TW202410890A (zh) | 使用ｃｄｋ４／６抑制劑後發展之ｅｒ⁺乳癌之拉索昔芬（ｌａｓｏｆｏｘｉｆｅｎｅ）組合治療 | |
| JP2025156341A (ja) | ＰＤ－１アンタゴニスト、ＨＩＦ－２α阻害剤およびレンバチニブまたはその薬学的に許容され得る塩の組み合わせを使用して、癌またはフォンヒッペル・リンダウ病を処置するための方法 | |
| Dudek et al. | Phase 1 study of TTC-352 in patients with metastatic breast cancer progressing on endocrine and CDK4/6 inhibitor therapy | |
| TW202423445A (zh) | 英菲格拉替尼在治療胃癌和腺癌中的用途 | |
| CN114746094A (zh) | 图卡替尼联合卡培他滨和曲妥珠单抗治疗her2阳性乳腺癌的方法 | |
| Newhook et al. | Adjuvant trametinib delays the outgrowth of occult pancreatic cancer in a mouse model of patient-derived liver metastasis | |
| KR20260008112A (ko) | 파르네실트랜스퍼라제 억제제 및 pi3k 억제제를 사용한 편평 세포 암종의 치료 방법 | |
| Mukai et al. | The Japanese breast Cancer Society clinical practice guideline for systemic treatment of breast cancer |